What INTRA-KER does

INTRA-KER is an Italian clinical-stage medtech company, spun out of the University of Ferrara (UNIFE), developing a hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who are not candidates for conventional donor transplantation. The company's core technology centers on a patented biological wrap designed to overcome the principal failure modes of existing artificial corneas — retroprosthetic membrane formation, tissue melt, and chronic inflammation — which currently drive complication rates as high as 70% and leave roughly half of recipients legally blind within one year. The device targets the estimated 12.7 million patients worldwide awaiting corneal transplants and the roughly 8,000 annual cases in which donor grafts fail, an addressable population that is structurally underserved by the limited global supply of 185,000 donor transplants per year.

The company is led by Professor Massimo Busin (President and CEO), a high-volume corneal surgeon, with Angeli Christy Yu (MD, PhD) as CTO and Vittorio Guarini handling business development contacts. INTRA-KER has built a multi-partner ecosystem including Eliachar Technology for surgical instrumentation, Fondazione Banca degli Occhi del Veneto for tissue supply, LIRFO and UNIFE for clinical and academic collaboration, and XPANCEO for a follow-on "smart cornea" platform. The company obtained Italian Ministry of Health authorization for clinical investigation in October 2025 and is scheduled to begin a clinical trial on 30 identified patients in November 2025, following a first-in-human transplant performed in October 2024 on a Palestinian refugee patient.

INTRA-KER is pre-revenue and is raising its first external funding round of €1.5 million, with approximately 85% allocated to R&D and clinical trial execution. Its intended go-to-market is a regulated Class III implantable device sold to hospitals and ophthalmology centers on a per-procedure basis, with CE marking under EU-MDR as the likely first commercial milestone. The business model hinges on converting clinical-trial success into premium-pricing reimbursement for a device positioned against both donor tissue and inferior existing keratoprostheses.

Name

INTRA-KER

Legal name

INTRA-KER Srl

Website

https://intra-ker.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

INTRA-KER is an Italian clinical-stage medtech spin-off from the University of Ferrara developing a patented hybrid artificial cornea (keratoprosthesis) for patients with severe corneal blindness who lack alternatives to donor transplantation.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

SIC

Optical Instruments & Lenses (3827)

akta.pro primary industry

Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

akta.pro secondary industries

Ophthalmic Regeneration (cornea/retina) (HLAAAGAK), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

Keywords

• Artificial cornea implants
• Hybrid keratoprosthesis
• Ophthalmic medical devices
• Corneal blindness treatment
• Intracorneal devices

Headquarters

HQ city

Forlì

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Commercialization: Pre-revenue clinical stage company. Revenue model will be derived from the sale of hybrid artificial cornea devices to hospitals and ophthalmology centers upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

INTRA-KER develops and is clinically validating a hybrid intracorneal device (hybrid artificial cornea) for corneal transplantation. The device combines a patented optical component with a biological wrap that integrates with host tissue, addressing limitations of traditional corneal transplants including immune rejection, endothelial cell loss, infection risk, and donor cornea scarcity. The company is conducting human clinical studies in Italy following Ministry of Health approval.

Product overview

INTRA-KER is a clinical-stage medtech company developing a single unified product: the INTRA-KER Hybrid Intracorneal Device (hybrid artificial cornea). This device combines a patented optical component with a biological wrap that integrates with host tissue. The company is also collaborating with XPANCEO on a future 'smart cornea' that would incorporate electronic capabilities to project images onto the retina. The current hybrid device is designed as an alternative to traditional corneal transplantation, addressing limitations including immune rejection, scarcity of donor tissue, and high complication rates.

Differentiator

Problem solved

Functional benefit

Products and services

• INTRA-KER Hybrid Intracorneal Device (Hybrid Artificial Cornea) A hybrid intracorneal device (keratoprosthesis) combining a patented optical component with a biological wrap for corneal transplantation. The device is extraocular for safe implantation, stable allowing storage over 12 months, transparent for light transmission, acellular to obviate immune rejection risk, biologic for stable bio-integration, and independent of endothelial function. Designed for hospitals and ophthalmology centers treating patients with corneal blindness who cannot be treated by traditional donor cornea transplantation.

Quantifiable outcome

• Over 185,000 corneal transplants performed annually using traditional methods globally
• +4 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• XPANCEOcoreStrategic or Co-development Partner · 3 September 2025Strategic collaboration with XPANCEO, a deep tech company pioneering optical and electronic integration. Together the companies aim to evolve the hybrid cornea into a future 'smart cornea' capable of restoring and even enhancing vision. The collaboration has produced an intracorneal implant prototype that projects images onto the retina, representing a significant advancement in vision restoration technology.
• Eliachar TechnologycoreTechnology or IntegrationR&D partnership for applied research on the use of optical lenses and projectors to replace the diseased cornea. Eliachar Technology collaborated with INTRA-KER beginning in 2021 for initial R&D phase development.
• Fondazione Banca degli Occhi del VenetocoreStrategic or Co-development PartnerThe Venice Eye Bank (Fondazione Banca degli Occhi del Veneto) partnered with INTRA-KER for the presentation of the first Italian Hybrid Keratoprosthesis. This partnership validates the technology through established ophthalmology institutions.
• University of Ferrara (UNIFE)coreStrategic or Co-development PartnerINTRA-KER is a UNIFE spin-off company, indicating a formal academic partnership for research and development of the hybrid corneal prosthesis technology.
• LIRFO (Istituto Internazionale di Ricerca Formazione Orientamento)minorOthersListed as a partner organization on the INTRA-KER About page, representing an international research and training institute collaboration.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Keramed Inc. Keramed manufactures the KeraKlear artificial cornea, a foldable keratoprosthesis directly competing with INTRA-KER's hybrid intracorneal device in the corneal blindness segment. Both target patients unsuitable for traditional donor transplantation and pursue similar regulatory and surgeon-training pathways.
• BostonSight: BostonSight is associated with the Boston Keratoprosthesis (Boston KPro), the most widely implanted FDA-cleared artificial cornea globally and INTRA-KER's primary benchmark for clinical performance. It serves the same end-patient population (severe corneal disease) and competes for surgeon adoption in the same ophthalmology centers.
• LinkoCare Life Sciences AB: LinkoCare is developing the LinkCor artificial cornea, a synthetic, cell-free keratoprosthesis that mirrors INTRA-KER's positioning on acellular, donor-independent corneal replacement. It is one of the closest mechanistic analogues to INTRA-KER's hybrid design.
• DIOPTEX Medizinprodukte Forschungs- und Vertriebs GmbH: DIOPTEX develops and distributes artificial corneas (including the KPro line) for corneal blindness, positioning it as a direct product competitor in the European keratoprosthesis market where INTRA-KER also operates.

Emerging players

• Aurolab: Aurolab manufactures the AuroKPro, a low-cost keratoprosthesis designed for emerging markets where donor tissue is most scarce. INTRA-KER's hybrid device competes in the same value-based segment and is likely to be benchmarked against AuroKPro on cost in developing-market expansion.
• Precise Bio: Precise Bio is advancing 3D bio-printed corneal grafts targeting endothelial and full-thickness corneal disease. While their modality differs (printed tissue vs. synthetic hybrid), they address the same donor-shortage unmet need and compete for the same ophthalmology centers and venture capital.

Broad incumbents

• Alcon Inc. Alcon is the largest dedicated ophthalmology device company globally, with a broad cataract, refractive, and surgical portfolio. It represents the most likely large strategic acquirer for a successful keratoprosthesis asset and the dominant commercial channel for any approved corneal device.
• CorneaGen: CorneaGen is a leading eye-bank and corneal tissue provider serving transplant surgeons globally. As a dominant donor-cornea supplier, it represents both a complement and competitive incumbent whose network and surgeon relationships INTRA-KER must navigate for adoption.
• Carl Zeiss Meditec AG: Carl Zeiss Meditec is a global ophthalmic device incumbent offering surgical microscopes, IOLs, and laser systems used alongside corneal transplantation. While not a direct artificial-cornea competitor, it is a potential strategic acquirer and controls key distribution channels INTRA-KER would need to access.
• Bausch + Lomb (Bausch Health): Bausch + Lomb is a diversified ophthalmology player covering surgical, vision care, and pharmaceuticals. It is a relevant strategic acquirer and competing portfolio company whose keratoprosthesis partnerships and surgical channels could overlap with INTRA-KER's go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INTRA-KER